global clinical trials for alzheimers disease

Download or Read online Global Clinical Trials For Alzheimers Disease full HQ books. Available in PDF, ePub and Kindle. We cannot guarantee that Global Clinical Trials For Alzheimers Disease book is available. Click Get Book button to download or read books, you can choose FREE Trial service. Join over 650.000 happy Readers and READ as many books as you like (Personal use).

Global Clinical Trials for Alzheimer s Disease
Author :
Publisher : Academic Press
Release Date :
ISBN 10 : 0124115306
Pages : 432 pages
Rating : /5 ( users)
GET BOOK!

Global Clinical Trials for Alzheimer’s Disease is a handy one-stop reference for researchers and physicians planning and conducting global clinical trials in this area. This book addresses important considerations that may arise during the successful design and execution of these trials, including site selection, local regulatory issues, pharmacogenomics, ethical matters and much more. Given the saturation of traditional clinical trial markets and the worldwide progression of Alzheimer’s disease, there is a need to focus on clinical trials in emerging markets and developing countries. This book provides you with a practical approach to recognizing the opportunities and tackling the challenges that are present during the planning and execution of global clinical trials for Alzheimer’s disease. Written by leading experts with hands-on experience in designing and running global Alzheimer’s disease and other neurodegenerative diseases clinical trials A step-by-step guide that provides critical information on the design, conduct and standardization necessary to effectively execute clinical trials and accelerate drug development in this area Includes practical examples, ethical considerations, lessons learned and other valuable tools to aid the planning and implementation of Alzheimer’s disease global clinical trials in emerging markets and developing countries

Global Clinical Trials for Alzheimer s Disease

Global Clinical Trials for Alzheimer’s Disease is a handy one-stop reference for researchers and physicians planning and conducting global clinical trials in this area. This book addresses important considerations that may arise during the successful design and execution of these trials, including site selection, local regulatory issues, pharmacogenomics, ethical

GET BOOK!
Global Clinical Trials for Alzheimer   s Disease

China has the largest number of people with dementia and the incidence is projected to increase much faster than in the developed world. There is a great demand for new drugs that can prevent or treat the disease and great potential for conducting Alzheimer’s disease clinical trials. The majority

GET BOOK!
Global Clinical Trials for Alzheimer   s Disease

Globalization is increasingly common as a means of more rapidly recruiting patients, shortening clinical trials, abbreviating clinical development cycle times, and preparing for marketing in non-US markets. Globalization refers to the inclusion of trial sites in three or more international regions. Globalization is common and most drug development programs include

GET BOOK!
Global Clinical Trials for Alzheimer   s Disease

Turkey straddles the continents of Europe and Asia, and this unique geographical location steers its economy. On the world economic scale, as an exceptional emerging economy, Turkey is the 16th largest economy in the world and the sixth largest economy as compared with the European Union countries, according to gross

GET BOOK!
Global Clinical Trials for Alzheimer   s Disease

A rapid increase in the globalization of clinical trials is being driven by a need for lower cost, greater speed, and higher quality. Increasing costs—approximately 20% per year—account for much of this effort. Trials in developing countries—done with rigorous controls and safeguards—can lower the cost of drugs,

GET BOOK!
Global Clinical Trials for Alzheimer   s Disease

Prevalence of dementia in Korea is 9.1% of the elderly population, and those with dementia are thus estimated to be nearly 750,000. Dementia due to Alzheimer’s disease (AD) accounts for 45–75% of all dementia syndromes, whereas vascular dementia accounts for about 12–37%. Clinical research on AD has been greatly expanded in volume and

GET BOOK!
Global Clinical Trials for Alzheimer   s Disease

Considering the difficulty of clinical development for Alzheimer’s Disease (AD), understanding each country’s specific situation is an important first step in reducing the operational burden on clinical trials while maintaining the quality of the study. In this chapter, the long history of clinical development for AD in Japan

GET BOOK!
Global Clinical Trials for Alzheimer   s Disease

This chapter provides an overview of the increasingly important role of emerging markets in Alzheimer’s disease trials, particularly Eastern Europe, where there is a robust population of accurately diagnosed subjects for trial participation, and recruitment rates are on a par with those in Western Europe and the USA. Some

GET BOOK!
Global Clinical Trials for Alzheimer   s Disease

The incidence of Alzheimer’s disease is increasing worldwide. The need to fortify global resources conducting clinical trials becomes of paramount importance for sponsors to ensure less delay in marketing their products. This chapter provides a concise and practical approach to building capacity and capability in emerging or developing markets.

GET BOOK!
Global Clinical Trials for Alzheimer   s Disease

There is considerable interest, both nationally and internationally, in conducting dementia research in India. Motivated by a rapid increase in the aging population and a desire for indigenous, self-sufficient healthcare and medical research, dementia research in India is on course for rapid growth in the coming years. Several challenges will

GET BOOK!
Global Clinical Trials for Alzheimer   s Disease

To date (2013), we have witnessed over 100 years of research on Alzheimer’s disease (AD). In the past century, this gave new and deep insights into its pathophysiology. However, no new treatment with an innovative mode of action has found its way to the patients since the first targeted therapies with

GET BOOK!
Global Clinical Trials for Alzheimer   s Disease

Data from clinical trials in emerging markets are becoming a standard component of the regulatory package being provided to support pharmaceutical marketing authorizations including the FDA New Drug Application (NDA) and the EMA Marketing Authorization Application (MAA). In this chapter, the highlights of the requirements for Alzheimer’s disease interventions

GET BOOK!
Global Clinical Trials for Alzheimer   s Disease

Decades ago, pharmacogenetic research established that one’s genetic profile might predict efficacy and safety of medicines. Polymorphic expression of isoenzymes of the cytochrome P-450 enzyme system explains a significant amount of the variability of inter-individual responses to medicines. In Alzheimer’s disease, the highly variable clinical response to cholinesterase

GET BOOK!
Global Clinical Trials for Alzheimer   s Disease

More than 35 million people worldwide are living with dementia, the vast majority Alzheimer’s disease (AD)-related. By 2050, Alzheimer’s disease cases will triple to 115 million—one new case every four seconds—placing untold stress on overburdened social service and healthcare delivery systems, a potentially catastrophic global epidemic. Sixty percent

GET BOOK!
Global Clinical Trials for Alzheimer   s Disease

About 2% of the United States population gets involved with clinical research trials each year; among those people who suffer from severe, chronic illnesses (including Alzheimer’s disease), only 6% participate. As a result, an increasing number of clinical trials are delayed because too few people ever know they had an opportunity

GET BOOK!